NKX2-5-Related Congenital, Conduction and Myopathic Heart Disease — Comprehensive Research Report

Disease: NKX2-5-Related Congenital, Conduction and Myopathic Heart Disease MONDO ID: MONDO:0800441 · OMIM: #108900 (ASD7, atrial septal defect 7 with or without atrioventricular conduction defects) Causal gene: NKX2-5 (NK2 homeobox 5; formerly CSX, cardiac-specific homeobox; HGNC:2488; chromosome 5q35.1) Category: Mendelian, autosomal dominant

Causal gene stated up front: This report concerns the disease caused by heterozygous, predominantly loss-of-function variants in NKX2-5, the homeodomain cardiac transcription factor located at chromosome 5q35.1 (the vertebrate homolog of Drosophila tinman). The hallmark combination is secundum atrial septal defect (ASD) with progressive atrioventricular (AV) conduction block, together with a broader spectrum of structural malformations and a myopathic/conduction-cell component. All molecular claims below refer to NKX2-5, not to similarly named genes.

Summary

NKX2-5-Related Congenital, Conduction and Myopathic Heart Disease is an autosomal-dominant cardiac disorder caused by heterozygous, predominantly loss-of-function (haploinsufficient) variants in NKX2-5, the NK2-class homeodomain cardiac transcription factor located at chromosome 5q35.1. NKX2-5 is the vertebrate ortholog of the Drosophila cardiac selector gene tinman and is one of the earliest and most essential regulators of cardiac development. The disease was first defined genetically by Schott et al. (1998), who mapped a dominant locus for cardiac malformations plus atrioventricular (AV) conduction abnormalities to 5q35 and identified disease-causing NKX2-5 mutations, two of which impair DNA binding and thereby cause haploinsufficiency [PMID: 9651244].

The clinical syndrome unites three mechanistically linked manifestations. First, structural congenital heart defects — most characteristically secundum atrial septal defect (ASD), but also ventricular septal defect (VSD), tetralogy of Fallot, double-outlet right ventricle, and Ebstein anomaly — arising from NKX2-5's role in cardiac looping and septation. Second, a progressive atrioventricular conduction disease: the AV node is hypoplastic from birth in a gene-dosage-dependent manner, then undergoes selective postnatal dropout of conduction cells, producing age-progressive AV block that was the primary cardiac manifestation in roughly a quarter of affected individuals in the landmark Benson et al. cohort [PMID: 10587520]. Third, a myopathic branch — trabecular/ventricular non-compaction and cardiomyopathy — driven in model systems by ectopic, high-level BMP10 expression in ventricular myocardium when NKX2-5 is lost [PMID: 15109497].

The mechanistic chain is well supported by a mouse allelic series. Homozygous-null embryos form a linear heart tube but fail to initiate looping morphogenesis and die at E9–10, lacking the ventricular marker MLC2V [PMID: 7628699]. Heterozygotes model human haploinsufficiency, with roughly half the normal number of conduction-system cells and a hypoplastic AV node [PMID: 15085192]. Ventricular-restricted conditional knockouts reproduce progressive complete heart block together with trabecular overgrowth via ectopic BMP10 [PMID: 15109497]. Management is phenotype-directed — surgical/device septal closure, permanent pacemaker/ICD for conduction disease and sudden-death risk, and heart-failure therapy — with no gene-specific cure currently available.

Section 1 — Disease Information and Key Identifiers

Synonyms / alternative names: NKX2-5-related congenital heart disease; atrial septal defect with atrioventricular conduction defects; CSX-related congenital heart disease; cardiac homeobox (CSX) disease. The gene has historically been written NKX2.5, NKX2E, and CSX.

Source of information: The content of this report is derived from aggregated disease-level resources — OMIM, MONDO, and primary peer-reviewed human genetic/clinical studies and model-organism literature — rather than from individual-patient electronic health records.

Section 2 — Etiology

Primary cause (genetic): Heterozygous pathogenic variants in NKX2-5. The predominant molecular mechanism is haploinsufficiency: variants that reduce functional NKX2-5 dosage (truncating variants, and missense variants that impair DNA binding) are sufficient to cause disease [PMID: 9651244]. Some variants may additionally act via dominant-negative effects or reduced transactivation.

Genetic risk factors: The causal NKX2-5 variant is itself the principal genetic determinant. Partner cardiac transcription factors (GATA4, TBX5, TBX20, GATA6) that function combinatorially with NKX2-5 cause overlapping CHD phenotypes when mutated and are candidate modifiers.

Environmental risk factors: No specific environmental trigger is established for NKX2-5-related disease. General CHD risk factors (maternal diabetes, teratogen exposure, folate status) may plausibly modify expressivity but are not documented as disease-specific for this entity.

Protective factors: None established genetically or environmentally specific to this disease.

Gene–environment interactions: Variable expressivity within families carrying the same variant (Benson et al.) implies the existence of genetic modifiers and/or environmental contributors, but none are specifically characterized [PMID: 10587520].

Section 3 — Phenotypes

Benson et al. (2000) documented across mutation carriers: AV block (primary manifestation in ~25%), secundum atrial septal defect, ventricular septal defect, tetralogy of Fallot/double-outlet right ventricle (3 individuals), and Ebstein anomaly/tricuspid valve abnormalities [PMID: 10587520]. Schott et al. emphasized that NKX2-5 is important both for septation during cardiac morphogenesis and for maturation and maintenance of AV node function throughout life — i.e., a lifelong, progressive course [PMID: 9651244].

"Ventricular septal defect was associated with tetralogy of Fallot or double-outlet right ventricle in 3 individuals. Ebstein's anomaly and other tricuspid valve abnormalities were also present." — [PMID: 10587520]

"NKX2-5 is important for regulation of septation during cardiac morphogenesis and for maturation and maintenance of atrioventricular node function throughout life." — [PMID: 9651244]

Suggested HPO annotations:

Quality of life impact: Pacemaker dependence, activity restriction from heart failure/arrhythmia, surgical burden, and lifelong surveillance affect daily functioning; sudden-death risk imposes substantial psychological burden on patients and families.

Section 4 — Genetic / Molecular Information

Causal gene: NKX2-5 (HGNC:2488; OMIM gene 600584). Disease OMIM: #108900.

Pathogenic variants: Reported variants include missense (notably within/affecting the homeodomain, impairing DNA binding), nonsense, frameshift, and splice-site changes. Schott et al. identified 3 mutations (2 DNA-binding-impairing) [PMID: 9651244]; Benson et al. added 7 novel mutations across 26 probands [PMID: 10587520]. Variant classification follows ACMG/AMP criteria in ClinVar (pathogenic/likely pathogenic for established LoF alleles).

Allele frequency: Pathogenic NKX2-5 variants are rare and largely family-private; they are essentially absent/ultra-rare in gnomAD, consistent with a highly constrained developmental transcription factor.

Somatic vs. germline: Germline (congenital disorder). De novo and inherited dominant variants both occur.

Functional consequences: Predominantly loss of function / haploinsufficiency; impaired DNA binding is a demonstrated mechanism [PMID: 9651244]. Dominant-negative effects have been proposed for some variants.

Modifier genes: GATA4, TBX5, TBX20, GATA6 (combinatorial partners) are candidate modifiers; variable expressivity implies modifiers but none are definitively mapped.

Epigenetic / chromosomal: No disease-specific methylation signature is established. Large 5q35 deletions/structural changes involving NKX2-5 can produce the phenotype and are detectable by chromosomal microarray.

Section 5 — Environmental Information

No specific environmental factors, lifestyle factors, or infectious agents are established as causes or triggers of NKX2-5-related disease. The disorder is fundamentally genetic/developmental. General CHD environmental modifiers (maternal metabolic state, teratogens) are not documented as disease-specific for this entity. Not applicable / not established for this Mendelian condition.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain:

1. A heterozygous loss-of-function NKX2-5 variant (nonsense, frameshift, splice, or DNA-binding-impairing missense) leads to reduced functional NKX2-5 protein — i.e., haploinsufficiency (demonstrated for DNA-binding-impairing alleles; [PMID: 9651244]).
2. Reduced NKX2-5 dosage results in diminished combinatorial transcriptional activation (with GATA4/TBX5/GATA6) of chamber- and conduction-specific target genes (inferred from network studies; target genes shown in [PMID: 15109497, 15085192]).
3. Branch A — Structural: Impaired transcriptional program leads to failed/abnormal cardiac looping and septation during embryogenesis → results in secundum ASD, VSD, conotruncal defects (tetralogy of Fallot, DORV), and Ebstein anomaly (looping requirement demonstrated in null mice [PMID: 7628699]; human spectrum [PMID: 10587520]).
4. Branch B — Conduction: Reduced dosage leads to a hypoplastic AV node at birth (dosage-dependent cell number) → results in selective postnatal dropout/failed retention of conduction cells → leads to progressive first- → second- → third-degree AV block and sudden-death risk ([PMID: 15085192, 15109497]).
5. Branch C — Myopathic: Loss of NKX2-5 repression results in ectopic high-level BMP10 in ventricular myocardium → leads to trabecular overgrowth / ventricular non-compaction and cardiomyopathy (demonstrated in conditional KO; BMP10 necessary and sufficient for major ventricular muscle defects [PMID: 15109497]).

                    NKX2-5 LoF variant (heterozygous)
                                 │
                       Haploinsufficiency
                                 │
             Reduced combinatorial activation of
          chamber/conduction gene programs (GATA4/TBX5)
                                 │
        ┌────────────────────────┼─────────────────────────┐
        ▼                        ▼                          ▼
  [A] Looping/septation    [B] AV-node hypoplasia      [C] Loss of BMP10
      failure                  + cell dropout              repression
        │                        │                          │
  Secundum ASD, VSD,       Progressive AV block        Ectopic BMP10 →
  TOF, DORV, Ebstein       (1°→2°→3°), SCD risk        noncompaction/CMP

"looping morphogenesis, a critical determinant of heart form, was not initiated at the linear heart tube stage" — [PMID: 7628699]

"At birth, mutant mice display a hypoplastic atrioventricular (AV) node and then develop selective dropout of these conduction cells." — [PMID: 15109497]

"Transcriptional profiling uncovered the aberrant expression of a unique panel of atrial and conduction system-restricted target genes, as well as the ectopic, high level BMP-10 expression in the adult ventricular myocardium." — [PMID: 15109497]

Molecular / cellular detail: - Molecular pathways: NKX2-5 is a homeodomain transcription-factor node in the core cardiac gene-regulatory network; downstream effectors include GJA5/connexin40 (gap junction), BMP10 signaling, and chamber myocyte identity genes. Jay et al. identified connexin40 as a putative Nkx2-5 target [PMID: 15085192]. - GO biological processes: cardiac conduction (GO:0061337), heart looping (GO:0001947), cardiac septum morphogenesis (GO:0003279), regulation of transcription by RNA polymerase II (GO:0006357), cardiac muscle tissue development (GO:0048738). - Cell types (CL): nodal/AV-node myocyte (CL:0002087), cardiac Purkinje fiber cell (CL:0000166), ventricular cardiomyocyte (CL:0002131), atrial cardiomyocyte (CL:0002129), precardiac mesoderm. - Subcellular (GO CC): nucleus (GO:0005634, site of transcription-factor action), gap junction / connexin40 (GO:0005922). - Protein dysfunction: predominantly loss of function via impaired DNA binding (homeodomain mutations) or protein truncation; haploinsufficiency is the dominant paradigm [PMID: 9651244].

Section 7 — Anatomical Structures Affected

• Organ: Heart (UBERON:0000948) — primary. Secondary systemic effects from heart failure and conduction disease affect the cardiovascular system (UBERON:0004535).
• Structures: interatrial/atrial septum (UBERON:0002085) — secundum ASD; interventricular septum (UBERON:0002094) — VSD; atrioventricular node (UBERON:0002351) — conduction disease; cardiac conduction system (UBERON:0004146) and His–Purkinje system; cardiac ventricle (UBERON:0002082) and trabecular myocardium — non-compaction; tricuspid valve — Ebstein anomaly; cardiac outflow tract (UBERON:0004145) — conotruncal defects.
• Tissue/cell level: cardiac muscle (myocardium), specialized conduction myocytes, nodal myocytes.
• Subcellular: nucleus (transcription-factor action); gap junctions (connexin40).
• Lateralization: The heart is a midline organ; conotruncal/looping phenotypes reflect disrupted left–right morphogenesis rather than limb-type lateralization.

Section 8 — Temporal Development

• Onset: Congenital for structural defects (present at birth, often detected in infancy/childhood). Conduction disease is congenital-to-progressive — the AV node is hypoplastic from birth, but block severity worsens with age.
• Progression: The conduction phenotype is characteristically progressive, evolving from first-degree AV block in childhood to higher-grade/complete block in adulthood, reflecting ongoing conduction-cell dropout [PMID: 15085192, 15109497]. Structural defects are static once formed but may require intervention; the myopathic phenotype can emerge or progress over time.
• Critical period: Cardiac looping and septation (~embryonic weeks 3–8 in humans; E8–E10.5 in mouse) is the window in which structural defects originate.
• Course: Chronic, lifelong, requiring continued surveillance even after structural repair.

Section 9 — Inheritance and Population

• Inheritance: Autosomal dominant (OMIM #108900).
• Penetrance / expressivity: Incomplete penetrance and markedly variable expressivity — family members with the same variant may have isolated AV block, isolated ASD, complex CHD, or be minimally affected [PMID: 10587520].
• Epidemiology: CHD overall affects ~0.8% of live births; NKX2-5 variants account for an estimated ~1–4% of nonsyndromic CHD (established-knowledge estimate). Benson et al.: 7 novel mutations across 26 probands; authors conclude NKX2-5 may account for a clinically significant portion of tetralogy of Fallot and idiopathic AV block [PMID: 10587520].
• Sex ratio: No strong sex bias (autosomal).
• Founder effects / consanguinity: Not prominent; most variants are family-private. Not a repeat-expansion disorder, so genetic anticipation is not expected. Germline mosaicism is possible but not a documented recurrent feature.

"Mutations in human NKX2.5 cause a variety of cardiac anomalies and may account for a clinically significant portion of tetralogy of Fallot and idiopathic AV block." — [PMID: 10587520]

"The coinheritance of NKX2.5 mutations with various congenital heart defects suggests that this transcription factor contributes to diverse cardiac developmental pathways." — [PMID: 10587520]

Section 10 — Diagnostics

• Electrophysiology: 12-lead ECG and ambulatory (Holter) monitoring are central for detecting and staging AV block (PR-interval prolongation → higher-grade block); serial surveillance is essential given progression.
• Imaging: Transthoracic echocardiography detects secundum ASD, VSD, conotruncal anomalies, Ebstein anomaly, and ventricular non-compaction; cardiac MRI quantifies non-compaction and ventricular function.
• Genetic testing: Single-gene NKX2-5 sequencing, multigene congenital-heart/cardiomyopathy/conduction panels, or whole-exome/genome sequencing. Recommended for probands with CHD plus conduction disease and for cascade screening of relatives. Chromosomal microarray detects larger 5q35 structural changes.
• Clinical criteria / differential diagnosis: Secundum ASD (or other CHD) with progressive AV block is highly suggestive. Differentials include GATA4-, TBX5- (Holt–Oram, distinguished by radial/upper-limb anomalies), and TBX20-related CHD; isolated idiopathic AV block (Lev–Lenègre); and Lamin A/C conduction disease.
• Screening: Cascade genetic and clinical (ECG/echo) screening of at-risk relatives is the key secondary-prevention measure.

Section 11 — Outcome / Prognosis

• Mortality: Driven chiefly by high-grade AV block (syncope, sudden cardiac death) and by complications of structural defects and cardiomyopathy. Sudden death has been reported even after structural repair, underscoring the need for conduction surveillance.
• Morbidity: Heart failure (from cardiomyopathy/non-compaction or unrepaired shunts), thromboembolic risk, pacemaker dependence.
• Prognostic factors: Degree/progression of AV block, presence of ventricular dysfunction/non-compaction, and complexity of the structural lesion. Timely pacemaker/ICD implantation and surgical repair substantially improve outcomes.
• Recovery: Structural defects are correctable; conduction disease is managed but not cured and tends to progress.

Section 12 — Treatment

No gene-specific or curative therapy exists; management is phenotype-directed.

• Pharmacogenomics / advanced therapeutics: No approved gene, cell, or RNA-based therapy. Gene-replacement/editing remains preclinical. No targeted small molecule exists for NKX2-5 disease.
• Treatment strategy: Lifelong multidisciplinary follow-up (congenital cardiology + electrophysiology), serial ECG/Holter and echo, with device therapy timed to conduction progression.

Section 13 — Prevention

• Primary prevention: Not applicable in the classical sense (congenital genetic disorder); preconception genetic counseling and reproductive options (prenatal/preimplantation genetic testing) can prevent transmission.
• Secondary prevention: Cascade genetic and ECG/echocardiographic screening of first-degree relatives enables early detection of silent conduction disease and timely pacemaker placement — the single most impactful preventive measure given the progressive, sudden-death-prone conduction phenotype.
• Tertiary prevention: Device therapy (pacemaker/ICD), heart-failure management, and anticoagulation to prevent complications.
• Counseling: Autosomal-dominant genetic counseling with 50% transmission risk per pregnancy; emphasis on incomplete penetrance and variable expressivity.

Section 14 — Other Species / Natural Disease

• Taxonomy of orthologs: Mouse (Mus musculus, NCBI Taxon 10090; Nkx2-5, NCBI Gene 18091); zebrafish (Danio rerio, Taxon 7955; nkx2.5); Drosophila melanogaster (Taxon 7227; tinman, the founding ortholog).
• Evolutionary conservation: Deep conservation of cardiac selector function — tinman mutants in Drosophila lack a heart, establishing the ancestral role. NKX2-5 expression in precardiac mesoderm and myocardium is conserved [PMID: 7628699].
• Natural disease in companion animals/wildlife: Not a prominently catalogued naturally occurring NKX2-5 disease in veterinary species (OMIA); conservation implies orthologous roles but spontaneous disease is not a documented entity. Not applicable / not established for veterinary natural disease.

Section 15 — Model Organisms

• Mouse (Mus musculus; Nkx2-5): The definitive model system with a graded allelic series:
• Homozygous knockout — embryonic-lethal (E9–10), failed cardiac looping, absent MLC2V [PMID: 7628699].
• Heterozygotes — model human haploinsufficiency; hypoplastic AV node, ~50% reduction in conduction-system cellularity [PMID: 15085192].
• Ventricular-restricted conditional knockout — progressive complete heart block, trabecular overgrowth / non-compaction via ectopic BMP10 [PMID: 15109497].
• Phenotype recapitulation: Strong and dosage-graded, faithfully reproducing both the conduction and myopathic branches of human disease.
• Limitations: Homozygous lethality prevents study of adult null hearts without conditional strategies; mouse–human differences in conduction-system anatomy.
• Zebrafish (nkx2.5): Useful for developmental and regenerative cardiac studies.
• Resources: MGI (mouse), ZFIN (zebrafish), FlyBase (tinman), Alliance of Genome Resources.

"In Nkx2-5 haploinsufficiency, the conduction system has half the normal number of cells." — [PMID: 15085192]

"The murine homeo box gene Nkx2-5 is expressed in precardiac mesoderm and in the myocardium of embryonic and fetal hearts." — [PMID: 7628699]

Key Findings (consolidated with evidence)

Finding 1 — NKX2-5 haploinsufficiency causes autosomal-dominant CHD with secundum ASD and progressive AV conduction block

Schott et al. (1998) mapped a dominant locus for cardiac malformations plus AV conduction abnormalities to 5q35 (NKX2-5) and identified 3 mutations, 2 impairing DNA binding → haploinsufficiency [PMID: 9651244]. Benson et al. (2000) found 7 novel mutations in 26 probands; AV block was the primary manifestation in ~25%, alongside ASD and VSD [PMID: 10587520].

"A dominant disease locus associated with cardiac malformations and atrioventricular conduction abnormalities was mapped to chromosome 5q35, where NKX2-5, a Drosophila tinman homolog, is located." — [PMID: 9651244] "Two are predicted to impair binding of NKX2-5 to target DNA, resulting in haploinsufficiency" — [PMID: 9651244] "Associated phenotypes included AV block, which was the primary manifestation of cardiac disease in nearly a quarter of affected individuals, as well as atrial septal defect and ventricular septal defect." — [PMID: 10587520]

Finding 2 — AV block arises from gene-dosage-dependent AV-node hypoplasia and progressive cell dropout

Jay et al. (2004): conduction-system cell number is directly proportional to Nkx2-5 dosage; heterozygotes have ~half the normal cells and lose a connexin40(−)/connexin45(+) AV-node population [PMID: 15085192]. Pashmforoush et al. (2004): hypoplastic AV node at birth followed by selective dropout causes progressive complete heart block [PMID: 15109497].

"We show in KO mice that the number of cells in the cardiac conduction system is directly related to Nkx2-5 gene dosage." — [PMID: 15085192] "Postnatal conduction defects in Nkx2-5 mutation may result at least in part from a defect in the genetic program that governs the recruitment or retention of embryonic cardiac myocytes in the conduction system." — [PMID: 15085192]

Finding 3 — Nkx2-5 is essential for cardiac looping and ventricular myogenic specification

Lyons et al. (1995): null embryos form a linear tube but fail looping and die E9–10; MLC2V is absent [PMID: 7628699].

"this gene is a component of a genetic pathway required for myogenic specialization of the ventricles" — [PMID: 7628699]

Finding 4 — Broad phenotypic spectrum (ASD predominant, progressive AV block, VSD/conotruncal/Ebstein, myopathy)

Documented in Benson et al. and Schott et al. [PMID: 10587520, 9651244] (see Section 3 table).

Finding 5 — NKX2-5 acts in a combinatorial network; targets include GJA5/connexin40 and BMP10

Jay et al. (connexin40 target) [PMID: 15085192]; Pashmforoush et al. (ectopic BMP10, aberrant conduction/chamber target genes) [PMID: 15109497].

Finding 6 — Autosomal dominant with incomplete penetrance / variable expressivity

Benson et al.: diverse coinherited CHD phenotypes; clinically significant contribution to TOF and idiopathic AV block [PMID: 10587520].

Finding 7 — Mouse models recapitulate the disease dosage-dependently; mechanism is deeply conserved

Allelic series across [PMID: 7628699, 15085192, 15109497]; conserved from Drosophila tinman through zebrafish nkx2.5.

Evidence Base

The evidence base is internally consistent: human genetic studies define the phenotype and the haploinsufficiency mechanism, and the mouse allelic series supplies the mechanistic causal chain, dosage dependence, and molecular mediators (connexin40, BMP10). The mouse and human data are mutually reinforcing.

Limitations and Knowledge Gaps

1. Quantitative penetrance/expressivity for each phenotype across large modern cohorts is incompletely captured; the Benson cohort (26 probands) is foundational but small.
2. Genotype–phenotype correlation — whether DNA-binding-missense vs. truncating variants preferentially cause conduction vs. structural vs. myopathic disease — is not fully resolved.
3. Modifier genes and gene–environment interactions are undefined despite clear variable expressivity.
4. Human BMP10 confirmation: the myopathic/BMP10 mechanism is robustly shown in mouse but direct human ventricular-tissue confirmation is limited.
5. Disease-specific prevalence as a standalone epidemiological figure was not individually retrieved; estimates derive from CHD-attributable-fraction literature.
6. Literature-fetch limitation: A PubMed esearch outage during the investigation locked the citation base to a verified set of efetch-confirmed landmark papers rather than an exhaustive recent-literature sweep.

Proposed Follow-up Experiments / Actions

1. Variant-stratified cohort analysis: Mine ClinVar/HGMD NKX2-5 variants and test genotype–phenotype correlation (truncating vs. homeodomain-missense vs. dominant-negative) against conduction, structural, and myopathic sub-phenotypes.
2. iPSC-cardiomyocyte modeling: Patient-derived iPSC-CMs with isogenic correction to quantify dosage effects on conduction (GJA5) and BMP10 expression, bridging mouse mechanism to human cells.
3. Natural-history registry query: Extract age-of-onset and progression-rate distributions for AV block to quantify the progressive-conduction model.
4. Modifier screen: GWAS/exome analysis within NKX2-5 families to identify modifier loci explaining variable expressivity.
5. BMP10 human validation: Examine BMP10 in explanted/biopsied ventricular myocardium from NKX2-5-mutant non-compaction patients.
6. Prospective pacing study: Correlate genotype with timing/necessity of pacemaker implantation to inform surveillance intervals.

Consensus Answer

NKX2-5-Related Congenital, Conduction and Myopathic Heart Disease (MONDO:0800441; OMIM #108900, ASD7) is an autosomal-dominant disorder caused by heterozygous, mostly loss-of-function (haploinsufficient) variants in NKX2-5, the NK2-class homeodomain cardiac transcription factor at 5q35.1 (vertebrate homolog of Drosophila tinman). Reduced NKX2-5 dosage impairs its combinatorial activation (with GATA4/TBX5/GATA6) of chamber- and conduction-specific gene programs, producing three linked manifestations: structural defects (characteristically secundum ASD, plus VSD, tetralogy of Fallot, Ebstein anomaly) from disrupted looping/septation; a dosage-dependent hypoplastic AV node with progressive postnatal conduction-cell dropout causing age-progressive AV block and sudden-death risk; and a myopathic branch (ventricular non-compaction/cardiomyopathy) driven by ectopic BMP10. Management is phenotype-directed (septal closure, pacemaker/ICD, heart-failure therapy) with no gene-specific cure, and the mechanism is faithfully recapitulated dosage-dependently in mouse models.